Market Overview
The Asia Pacific apheresis market encompasses equipment, disposables, and services used for blood component separation and collection in therapeutic and donor settings. The regional market was valued at approximately $0.82 billion in 2025, with multiple industry analyses projecting a compound annual growth rate near 10.5% through 2030 or 2031. Growth reflects expanding healthcare access, rising prevalence of conditions requiring apheresis therapy such as autoimmune disorders and blood cancers, and increasing adoption of cell-based therapies across the region.
- •Market size estimated at $0.82 billion in 2025, with projections to reach approximately $1.35 billion by 2030
- •Plasmapheresis machines represent a major segment, valued at $642 million in 2025 with its own 9.3% growth trajectory
- •The region represents a primary driver of global apheresis demand, outpacing other geographic markets in growth velocity
Growth Drivers
Increasing prevalence of chronic and lifestyle-related diseases such as renal disorders, autoimmune conditions, and hematological malignancies drives demand for apheresis-based therapies across Asia Pacific. Expanding healthcare infrastructure, rising awareness of advanced cell therapies, and growing blood donation and plasma collection programs further support market expansion. Automation and precision cell-separation technology adoption accelerate clinical efficiency and patient throughput in hospitals and collection centers.
- •Rising incidence of chronic diseases requiring therapeutic apheresis, including kidney failure and autoimmune disorders
- •Expanding blood and plasma collection infrastructure to support immunoglobulin and biopharmaceutical manufacturing
- •Advancements in automated apheresis platforms improving procedure safety, efficiency, and patient outcomes
Segmentation and Regional Analysis
The market comprises apheresis devices, disposables, and software across therapeutic apheresis, donor apheresis, and research applications. China is identified as the highest-growth country in the region during the forecast period, supported by large patient populations and healthcare modernization. Japan, South Korea, Australia, and India also contribute significantly, with varying adoption rates influenced by regulatory environments, healthcare spending, and medical tourism trends.
- •China expected to register the highest growth rate in the Asia Pacific region through 2030
- •Therapeutic apheresis applications account for a substantial share, driven by rising treatment utilization
- •Disposable component demand correlates with procedure volume growth across collection and therapeutic settings
Trends and Outlook
What are the recent trends and outlook?
The Asia Pacific apheresis market is positioned for sustained double-digit growth through 2030, supported by continued healthcare investment and expanding cellular therapy pipelines. Automation, miniaturization, and single-use disposable innovation are expected to enhance procedure accessibility and safety. Increasing adoption of autologous and allogeneic cell therapies, including CAR-T and stem cell treatments, will likely expand the addressable market for advanced apheresis platforms in coming years.
- •Cell therapy and regenerative medicine applications represent emerging high-growth opportunities for apheresis equipment
- •Automation and digital integration trends aim to reduce operator burden and improve procedure standardization
- •The region's demographic trends and healthcare modernization suggest long-term structural demand growth beyond 2030
Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.
Connect to an analyst →Market size and forecast are Claight Analysis, informed by public research and industry data. Historical years before 2025 and all forecast years are Claight estimates at the stated CAGR. Retrieved 2026.